Crossover Health
Travis has extensive experience in biotechnology and venture investing, leading transactions from seed investments to near-commercial assets. He has served as a director and board member for nonclinical and clinical stage companies, providing operational and management support to a portfolio of companies developing drugs across a broad spectrum of therapeutic focus, including orphan diseases, cardio-renal disorders, oncology, cell-therapy, and ophthalmology.
Prior to joining Gurnet Point Capital, Travis was President and CEO at Stealth BioTherapeutics, a late-stage clinical biotechnology company developing technologies to treat mitochondrial dysfunction in common and rare diseases. For more than a decade, he was a member of the life science investment team at the Morningside Group, a privately-held investment firm. With Morningside, he assisted with multiple financings, including several public and private companies such as Chimerix (NASDAQ: CMRX), Genocea (NASDAQ: GNCA), BioVex (acquired by Amgen), Aduro (NASDAQ: ADRO), and Argos (NASDAQ: ARGS).
Travis has lectured extensively on life science investing and management and is a long-time supporter of patient-advocacy groups. He holds a law degree and a chemical engineering degree, both from the University of Wisconsin.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Crossover Health
2 followers
Provides primary health services to self-funded employers by managing both worksite and nearby centers for employees and their dependents.